CASE 2
A 49-year-old man presented in February 2000 with melanoma (Clark level IV; Breslow thickness, 1.8 mm) on the left parietal region of the scalp. The melanoma was treated with wide and deep resection followed by split-thickness skin graft repair. A sentinel node was positive (micrometastases of melanoma) and radical lymph node dissection of the neck was performed. Other lymph nodes did not contain metastasis and there was no evidence of systemic disease. The patient received adjuvant low-dose interferon alfa-2b (3 million IU 3 times per week for 3 months) and chemotherapy (dacarbazine [DTIC-Dome; Bayer, Leverkusen, Germany], carboplatin, and fotemustine).
In July 2000, multiple local recurrences appeared around the surgical scar. Despite several treatment modalities, including excision, carbon-dioxide laser vaporation, and regional hyperthermia combined with x-ray treatment, new recurrences and in-transit metastases developed. In January 2001, we found multiple pigmented papules forming clusters and large confluent black plaques around the left ear and in the left parieto-occipital region ( Figure 3A shows state after 1 month of treatment).
HISTOPATHOLOGY
The primary tumors of both patients had histopathologic features typical of malignant melanoma. In patient 1 ( Figure 4A ), 2 biopsy specimens of skin lesions from the right lower leg, and in patient 2, 1 biopsy specimen of a retroauricular pigmented papule, showed metastatic melanoma with sheets of neoplastic melanocytes situated mainly in the upper dermis.
THERAPEUTIC CHALLENGE
In view of her age and cardiac insufficiency, patient 1 elected a less aggressive therapy for the melanoma metastases. Several treatment modalities had been attempted for patient 2, without success. The challenge was to find a therapeutic alternative for these patients.
SOLUTION
The 2 patients were enrolled in our study after giving their informed oral consent.
The novel topical immune response modifier imiquimod (Aldara; 3M Pharmaceuticals, St Paul, Minn) was used as a 5% cream, 3 times per week on Monday, Wednesday, and Friday in the evening and washed off in the morning. The cream was applied to the papules and nodules of metastatic melanoma with a 1-cm surrounding margin.
In patient 1, treatment was carried out for 4 months, and the lesions showed complete clearing with superficial scars and residual hyperpigmentation ( Figures 1B and  2B) . A control biopsy specimen from the right leg, obtained 4 months after the initial therapy, showed a thinned epidermis with a perivascular lymphoid infiltrate, mild fibrosis, and an increase of ectatic vessels ( Figure 4B) . The large ulcerated nodule showed complete clinical resolution ( Figure 2B ). No adverse effects occurred except mild peritumoral erythema. As of this writing, the patient has been followed up for 15 months without clinical evidence of recurrence.
Patient 2 also showed complete clearing of the skin lesions after 8 months of treatment with 5% imiquimod cream (3 times per week; the cream was also applied in the evening on the papules and plaques and washed off in the morning). At one of the target sites, we noticed erosions after 1 month ( Figure 3A) ; these healed rapidly after therapy was discontinued in this area for a short time. Results of follow-up examinations 4 months and 8 months later showed no evidence of recurrence of melanoma metastases ( Figure 3B ). In a control biopsy specimen from the gray-brown area above the left ear, we found a thickened papillary dermis marked by fibroplasia and a band of melanophages. Residual melanoma cells could not be detected.
COMMENT
Metastatic melanoma of the skin is extremely difficult to treat. Despite a variety of available options, including surgery, immunotherapy, chemotherapy, x-ray therapy, regional hyperthermia, and carbon-dioxide laser ablation, treatment is often unsuccessful.
We evaluated the efficacy of imiquimod, which has been formulated as a 5% cream, in 2 patients with metastases of melanoma to the skin. Chemically, imiquimod is a 1-(2-methylpropyl)-1H-imidazol [4,5-c] quinolin-4-amine with a molecular formula of C 14 H 16 N 4 . Imiquimod enhances the immune system by inducing the release of several cytokines, including interferon ␣, interleukin 12, and tumor necrosis factor ␣.
1
In their preliminary report on the treatment of a cutaneous melanoma metastasis, Steinmann et al 2 suggested that the application of imiquimod might result in the induction of melanoma-specific cytotoxic T cells by cross-presentation of melanoma antigens by dendritic cells. 2 Imiquimod was introduced especially for the treatment of external genital warts (including those in children) and has subsequently been found to be useful for the treatment of molluscum contagiosum, verrucae planae, herpes simplex virus 2 infection, stucco keratoses, basal cell carcinoma, superficial squamous cell carcinoma, and actinic keratoses. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] We observed complete clinical and histopathologic remission of papules, plaques, and nodules in 2 patients with metastatic melanoma to the skin. Our findings indicate that topical imiquimod is a novel and 
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